
Life Sciences
Boston Biotech Rezera Says Its Pill Boosts Semaglutide's Anti-Inflammatory Effect
Rezera reported positive Phase 2 results on October 7, 2026 for ruvonoflast combined with semaglutide in 82 adults with obesity.

Daily business news
The Boston Business Watch News Desk covers openings, closings, deals, hires and the day's business news, written from public reports and checked against its sources before publication.

Life Sciences
Rezera reported positive Phase 2 results on October 7, 2026 for ruvonoflast combined with semaglutide in 82 adults with obesity.





New Hospital
Groundbreaking
New CEO
Events